GENFF (Genflow Biosciences) Cash, Cash Equivalents, Marketable Securities : $0.35 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Genflow Biosciences Cash, Cash Equivalents, Marketable Securities?

Genflow Biosciences's quarterly cash, cash equivalents, marketable securities increased from Dec. 2023 ($0.87 Mil) to Jun. 2024 ($1.45 Mil) but then stayed the same from Jun. 2024 ($1.45 Mil) to Dec. 2024 ($0.35 Mil).

Genflow Biosciences's annual cash, cash equivalents, marketable securities declined from Dec. 2022 ($2.87 Mil) to Dec. 2023 ($0.87 Mil) and declined from Dec. 2023 ($0.87 Mil) to Dec. 2024 ($0.35 Mil).

Genflow Biosciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Genflow Biosciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genflow Biosciences Cash, Cash Equivalents, Marketable Securities Chart

Genflow Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

0.30

2.87

0.87

0.35

Genflow Biosciences Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			2.87	1.90	0.87	1.45	0.35

Genflow Biosciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Genflow Biosciences (OTCPK:GENFF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Genflow Biosciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Genflow Biosciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Genflow Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genflow Biosciences PLC (OTCPK:GENFF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

GENF:UK WQ5:Germany

Address

6 Heddon Street, London, GBR, W1B 4BT

Website

https://www.genflowbio.com

Genflow Biosciences PLC is a preclinical biotechnology company focused on developing biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process, and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.